N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype

Oncogene

Volumn 33, Issue 45, 2014, Pages 5274-5287

  Whitaker, H C ^a   Shiong, L L ^a   Kay, J D ^a   Gronberg H ^b   Warren, A Y ^a,c   Seipel, A ^b   Wiklund, F ^b   Thomas, B ^a   Wiklund, P ^b   Miller, J L ^a,c   Menon, S ^a   Ramos Montoya, A ^a   Vowler, S L ^a   Massie, C ^a   Egevad, L ^b   Neal, D E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

biomarker; colon cancer; NAALase; prognostic; prostate cancer

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; NAALADL2 PROTEIN, HUMAN; TUMOR MARKER;

CANCER GRADING; CANCER STAGING; CELL MOTION; CONFOCAL MICROSCOPY; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIGENS, SURFACE; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICROSCOPY, CONFOCAL; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84931062726     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.464     Document Type: Article

References (54)

1. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo J 2006; 25: 1375–1384. DOI: 10.1038/sj.emboj.7600969
2. Rojas C, Frazier ST, Flanary J, Slusher BS. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem 2002; 310: 50–54. DOI: 10.1016/S0003-2697(02)00286-5
3. Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ et al. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 2007; 67: 1791–1800. DOI: 10.1002/pros.20664
4. Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PT et al. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett 2012; 22: 3931–3934. DOI: 10.1016/j.bmcl.2012.04.110
5. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol 2012; 31: 144–154. DOI: 10.1016/j.urolonc.2012.04.016
6. Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS et al. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur J Biochem 2004; 271: 2782–2790. DOI: 10.1111/j.1432-1033.2004.04209.x
7. Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004; 13: 1627–1635. DOI: 10.1110/ps.04622104
8. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet 2009; 5: e1000319. DOI: 10.1371/journal.pgen.1000319
9. Tonkin ET, Smith M, Eichhorn P, Jones S, Imamwerdi B, Lindsay S et al. A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3. Human Genet 2004; 115: 139–148. DOI: 10.1007/s00439-004-1134-6
10. Statistics OfN. Cancer Statistics Registrations, England 2010.
11. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168–172. DOI: 10.1200/JCO.1999.17.1.168
12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–771. DOI: 10.1093/jnci/90.10.766
13. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451. DOI: 10.1001/jama.1997.03540420041027
14. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255–261. DOI: 10.1038/nrurol.2009.40
15. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012; 344: d7894. DOI: 10.1136/bmj.d7894
16. Augustin H, Mayrhofer K, Pummer K, Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2012; 73: 203–210. DOI: 10.1002/pros.22558
17. Botchorishvili G, Matikainen MP, Lilja H. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol 2009; 19: 221–226. DOI: 10.1097/MOU.0b013e32832a2d10
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22. DOI: 10.1016/j.ccr.2010.05.026
19. Bu H, Schweiger MR, Manke T, Wunderlich A, Timmermann B, Kerick M et al. Anterior gradient 2 and 3—two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. FEBS J 2013; 280: 1249–1266. DOI: 10.1111/febs.12118
20. Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL et al. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol 2013; 26: 849–859. DOI: 10.1038/modpathol.2012.238
21. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL et al. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate 2013; 73: 306–315. DOI: 10.1002/pros.22569
22. Qian X, Li C, Pang B, Xue M, Wang J, Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One 2012; 7: e37225. DOI: 10.1371/journal.pone.0037225
23. Wayner EA, Quek SI, Ahmad R, Ho ME, Loprieno MA, Zhou Y et al. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate 2012; 72: 1023–1034. DOI: 10.1002/pros.21508
24. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011; 30: 2719–2733. DOI: 10.1038/emboj.2011.158
25. Varisli L, Gonen-Korkmaz C, Syed HM, Bogurcu N, Debelec-Butuner B, Erbaykent-Tepedelen B et al. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells. Mol Cell Endocrinol 2012; 350: 107–117. DOI: 10.1016/j.mce.2011.11.027
26. Tsuchiya N, Kamei D, Takano A, Matsui T, Yamada M. Cloning and characterization of a cDNA encoding a novel heterogeneous nuclear ribonucleoprotein-like protein and its expression in myeloid leukemia cells. J Biochem 1998; 123: 499–507. DOI: 10.1093/oxfordjournals.jbchem.a021964
27. Conkright MD, Montminy M. CREB: the unindicted cancer co-conspirator. Trends Cell Biol 2005; 15: 457–459. DOI: 10.1016/j.tcb.2005.07.007
28. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013; 54: 380–387. DOI: 10.2967/jnumed.112.111203
29. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer 2013; S0959-8049: 00087–00087.
30. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4: 128ra39. DOI: 10.1126/scitranslmed.3003651
31. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81–85.
32. Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol 2012; 137: 918–930. DOI: 10.1309/AJCPF3QWIG8FWXIH
33. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem 1996; 271: 26329–26334. DOI: 10.1074/jbc.271.42.26329
34. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000; 19: 5606–5613. DOI: 10.1038/sj.onc.1203877
35. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999; 59: 1655–1664.
36. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 2011; 304: 1–7. DOI: 10.1016/j.canlet.2010.12.023
37. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008; 68: 492–497. DOI: 10.1158/0008-5472.CAN-07-2930
38. Liao CH, Yeh SC, Huang YH, Chen RN, Tsai MM, Chen WJ et al. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr Relat Cancer 2010; 17: 99–111. DOI: 10.1677/ERC-09-0050
39. Lee SF, Srinivasan B, Sephton CF, Dries DR, Wang B, Yu C et al. Gamma-secretase-regulated proteolysis of the Notch receptor by mitochondrial intermediate peptidase. J Biol Chem 2011; 286: 27447–27453. DOI: 10.1074/jbc.M111.243154
40. Varisli L, Gonen-Korkmaz C, Debelec-Butuner B, Erbaykent-Tepedelen B, Muhammed HS, Bogurcu N et al. Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3beta signaling, and its knockdown results in deregulated G2/M transition in prostate cells. DNA Cell Biol 2011; 30: 419–429. DOI: 10.1089/dna.2010.1128
41. Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D et al. Mechanisms of androgen receptor repression in prostate cancer. Biochem Soc Trans 2006; 34 (Pt 6): 1124–1127. DOI: 10.1042/BST0341124
42. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 2010; 5: e13363. DOI: 10.1371/journal.pone.0013363
43. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380–10385. DOI: 10.1073/pnas.0403954101
44. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80. DOI: 10.1186/gb-2004-5-10-r80
45. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 2008; 24: 2921–2922. DOI: 10.1093/bioinformatics/btn557
46. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007; 23: 2183–2184. DOI: 10.1093/bioinformatics/btm311
47. Smyth GK in Limma: Linear Models For Microarray Data (ed. Gentleman VCR, Dudoit S, Irizarry W, Huber R), (Springer, NY, USA, 2005).
48. Whitaker HC, Stanbury DP, Brinham C, Girling J, Hanrahan S, Totty N et al. Labeling and identification of LNCaP cell surface proteins: a pilot study. Prostate 2007; 67: 943–954. DOI: 10.1002/pros.20580
49. Thirkettle HJ, Girling J, Warren AY, Mills IG, Sahadevan K, Leung H et al. LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res 2009; 15: 3003–3013. DOI: 10.1158/1078-0432.CCR-08-2046
50. Bennett HL, Fleming JT, O'Prey J, Ryan KM, Leung HY. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis 2010; 1: e72. DOI: 10.1038/cddis.2010.50
51. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 2007; 38: 1547–1552. DOI: 10.1016/j.humpath.2007.03.014
52. Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol 2011; 223: 81–87. DOI: 10.1002/path.2795
53. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 2005; 25: 183–191.
54. Wu YY, Li H, Lv XY, Wei Q, Li X, Liu XY et al. Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R). Cell Biochem Funct 2008; 26: 467–477. DOI: 10.1002/cbf.1468